This analysis Warner-Chilcott Plc: PharmaVitae Report examines the historical and forecast performance for Warner-Chilcott in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
• Gain insight into Warner-Chilcott's strategic outlook across the next 6 years.
• Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source.
Browse All: Pharmaceuticals Market Research
Table Of Contents
ABOUT THIS REPORT
PharmaVitae Explorer database
Chapter structure
Strategic insight
Company introduction
Sales analysis
Financial analysis
Product analysis
Data sourcing
Analyst consensus
EXECUTIVE SUMMARY
Key findings
Warner Chilcott prescription pharma sales outlook
Warner Chilcott financial outlook
SWOT analysis
Weaknesses
Opportunities
Threats
STRATEGIC INSIGHT
Proctor & Gamble acquisition will shape performance through to 2016
Portfolio has undergone substantial change
Impact of expiries increased by narrower product focus
Patent expiries non-negotiable – pre-erosion cash flow critical to future expansion
P&G acquisition will drive superior operating performance…
and provide platform for further diversification and strategic evolution
COMPANY INTRODUCTION
Background
M&A history
No comments:
Post a Comment